Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04206020 · ClinicalTrials.gov registry record · Phase 3
Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome
A Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 610
- Enrollment target
- 4
- Study locations
NCT04206020: Completed Phase 3 study of Dry Eye Syndrome, sponsored by Mitotech.
NCT04206020 is a Phase 3 study of Dry Eye Syndrome that has completed, run by Mitotech. The registered enrollment target is 610 participants, above the 104-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (487% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04206020, a Phase 3 study of Dry Eye Syndrome, has completed, sponsored by Mitotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 610 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
Primary Outcome
Change of Ocular Discomfort Scale, scale ranged from 0 to 4 with 0 = No Discomfort and 4 = Constant Discomfort.
Conditions Studied
Interventions
- DRUG SkQ1 Vehicle Solution
- DRUG SkQ1 Ophthalmic Solution
Study Locations (4)
Arizona
- Arizona Eye Institute and Cosmetic Laser - Sun City West
Massachusetts
- Andover Eye Associates - Andover
Texas
- Eye Clinics of South Texas - San Antonio
Virginia
- Piedmont Eye Center - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2020-10-06 |
| Phase | Phase 3 |
What the finished NCT04206020 record still lists
NCT04206020 is an interventional study that assigns participants to a tested intervention. The registered 610 participants enrollment target is mid-sized for trials with a published cap, above the 104-participant average among 10 other Dry Eye Syndrome trials with a reported enrollment target (487% higher).
The record links to 1 condition, with Dry Eye Syndrome appearing as the primary indexed condition, and to 2 interventions - of which SkQ1 Vehicle Solution is the first listed.
NCT04206020 reports a single indexed study location in Arizona, Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT04206020 about?
NCT04206020 is a clinical study titled "Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome". The purpose of this study is to evaluate whether SkQ1 Ophthalmic Solution is safe and effective compared to Vehicle for the treatment of the signs and symptoms of dry eye syndrome.
What is the current status of trial NCT04206020?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 610 participants. The study started on 2019-12-20. Estimated completion is 2020-10-06.
What conditions does trial NCT04206020 study?
This clinical trial studies the following conditions: Dry Eye Syndrome.
What interventions are being tested in trial NCT04206020?
The interventions under investigation include: SkQ1 Vehicle Solution (DRUG), SkQ1 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04206020?
This trial is sponsored by Mitotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04206020 being conducted?
This trial has 4 study locations across Arizona, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04206020's enrollment target sits among peer trials
610 1st of 10 higher than 10 of 10 other Dry Eye Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SkQ1 as Treatment for Dry-eye Syndrome
COMPLETED · Phase 3
-
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
RECRUITING · Phase 1
-
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
COMPLETED · NA
-
Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Dry Eye
COMPLETED · Phase 2
-
Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease
COMPLETED · Phase 1
-
Effects of Dry Eye Treatments on the Ocular Surface
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT05838638 · 610 participants · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI